Cargando...
Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
BACKGROUND: Bevacizumab (Bev) has gained acceptance as an active agent in the treatment of epithelial ovarian cancer (EOC). Data is lacking on survival outcomes in patients who are re-treated with Bev after achieving a complete response to a Bev-containing regimen (BCR). Our primary objective was to...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2012
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3886294/ https://ncbi.nlm.nih.gov/pubmed/22885866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.08.001 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|